Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01684423 · ClinicalTrials.gov registry record · Phase 2
Oral Rivaroxaban in Children With Venous Thrombosis
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01684423 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 64 participants.
The verdict
NCT01684423, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Active comparator
- DRUG Rivaroxaban (BAY59-7939) suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-02-19 |
| Est. Completion | 2016-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01684423
The ClinicalTrials.gov registry entry for NCT01684423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT01684423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01684423 about?
NCT01684423 is a clinical study titled "Oral Rivaroxaban in Children With Venous Thrombosis". The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.
What is the current status of trial NCT01684423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2013-02-19. Estimated completion is 2016-09-01.
What interventions are being tested in trial NCT01684423?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Active comparator (DRUG), Rivaroxaban (BAY59-7939) suspension (DRUG).
Who is sponsoring clinical trial NCT01684423?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.